利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1005 条记录 (耗时 0.031 秒)

    METFORMIN-BASED IONIC CO-CRYSTALS
    61.
    发明申请
    METFORMIN-BASED IONIC CO-CRYSTALS 审中-公开
    基于METFORMIN的离子共晶体

    公开(公告)号：WO2012148252A3

    公开(公告)日：2012-12-20

    申请号：PCT/MX2012000043

    申请日：2012-04-20

    申请人： INST DE INVESTIGACION EN QUIMICA APLIC S A DE C V ,  LARA OCHOA JOSE MANUEL FRANCISCO

    发明人： LARA OCHOA JOSE MANUEL FRANCISCO

    IPC分类号： C07D417/12 ,  A61K31/155 ,  A61K31/4015 ,  A61K31/4439 ,  A61P3/10 ,  C07C279/26 ,  C07D207/38

    CPC分类号： C07C279/26 ,  C07D207/27

    摘要： The invention relates to two novel metformin-based compounds obtained using the antidiabetic agent glimepiride as a contra-ion in one case and using the antidiabetic agent pioglitazone as a contra-ion in the other case. The resulting spectroscopy, as well as an evaluation of the physicochemical properties thereof, indicate that, in the solid state, both compounds correspond to ionic co-crystals attracted by ionic forces and interactions of the hydrogen bond type. The physicochemical properties of the ionic co-crystals have been shown to have better intrinsic dissolution rates and improved solubilities in relation to those of the precursor contra-ions; properties that can impact favourably on the bioavailability of the novel active principles. Said improved novel active principles are formulated in oral solid pharmaceutical compositions such as tablets or caplets that have advantages over existing commercial tablets. Consequently, tablets containing these novel active principles provide an improved treatment for controlling blood glucose levels in patients with type II diabetes.

    摘要翻译： 本发明涉及在一种情况下使用抗糖尿病剂格列美脲作为拮抗剂获得的两种新的基于二甲双胍的化合物，并且在另一种情况下使用抗糖尿病剂吡格列酮作为拮抗剂获得。 所得到的光谱以及其物理化学性质的评估表明，在固态下，两种化合物都对应于由离子力和氢键类型的相互作用所吸引的离子共晶。 已经显示离子共晶体的物理化学性质具有较好的固有溶解速率和相对于前体对映体的溶解度的改善; 这些性质可以有利地影响新型活性成分的生物利用度。 所述改进的新型活性成分配制在口服固体药物组合物例如片剂或囊片中，其具有优于现有商业片剂的优点。 因此，含有这些新型活性成分的片剂为控制II型糖尿病患者的血糖水平提供了改善的治疗。

    COMPOSITIONS FOR ORAL AND NASAL HYGIENE
    62.
    发明申请
    COMPOSITIONS FOR ORAL AND NASAL HYGIENE 审中-公开
    口腔和鼻腔卫生组合物

    公开(公告)号：WO2012075257A3

    公开(公告)日：2012-09-20

    申请号：PCT/US2011062844

    申请日：2011-12-01

    申请人： UNIV GEORGIA ,  WANG BING-YAN ,  ZHAO TONG ,  CIANCIO SEBASTIAN ,  DOYLE MICHAEL

    发明人： WANG BING-YAN ,  ZHAO TONG ,  CIANCIO SEBASTIAN ,  DOYLE MICHAEL

    IPC分类号： A61K31/401 ,  A61K31/185 ,  A61K31/19 ,  A61K31/4015 ,  A61P31/04

    CPC分类号： A61K31/19 ,  A61K8/365 ,  A61K8/463 ,  A61K9/0043 ,  A61K9/0063 ,  A61K31/185 ,  A61Q11/00 ,  A61Q17/005 ,  A61K2300/00

    摘要： The present disclosure encompasses pharmaceutically acceptable antimicrobial compositions of an amount of levulinic acid and sodium dodecyl sulfate effective in reducing the microbial population of an internal cranial cavity of a recipient human or animal subject. The disclosure also provides methods for reducing a microbial population of an internal cranial cavity of a recipient human or animal comprising contacting the oral cavity or sinuses of the subject with a composition comprising between about 0.5% to about 5% by weight per volume of levulinic acid and between about 0.05% to about 2% by weight per volume of sodium dodecyl sulfate (SDS) and for a period effective in reducing a microbial population of the oral cavity.

    摘要翻译： 本公开内容包括一定量的乙酰丙酸和十二烷基硫酸钠的药学上可接受的抗微生物组合物，其有效减少受体人或动物受试者的内部颅腔的微生物群体。 本公开还提供了减少受体人或动物的内部颅腔的微生物群体的方法，包括使受试者的口腔或鼻窦与包含约0.5％至约5％（体积）乙酰丙酸的组合物接触 和约0.05％至约2％重量/体积的十二烷基硫酸钠（SDS），并有效降低口腔微生物群体的时间。

    CONTROLLED RELEASE LEVETIRACETAM FORMULATIONS
    63.
    发明申请
    CONTROLLED RELEASE LEVETIRACETAM FORMULATIONS 审中-公开
    受控释放的LEVETIRACETAM配方

    公开(公告)号：WO2011159491A3

    公开(公告)日：2012-06-28

    申请号：PCT/US2011039030

    申请日：2011-06-03

    申请人： MYLAN INC ,  MURTY MUMMINI ARUNA ,  LI BOYONG

    发明人： MURTY MUMMINI ARUNA ,  LI BOYONG

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/4015

    CPC分类号： A61K9/2027 ,  A61K9/2054 ,  A61K9/2866 ,  A61K31/4015

    摘要： Pharmaceutical compositions in the form of tablets are disclosed including water-soluble active ingredients such as levetiracetam and a polymer component which primarily includes water-insoluble polymers comprising between 60% and 100% of the polymer component in the tablet core, preferably the entire polymer component in the tablet core. The pharmaceutical compositions can also include an extended-release coating including both water-soluble and water-insoluble polymers.

    摘要翻译： 公开了片剂形式的药物组合物，包括水溶性活性成分如左乙拉西坦和聚合物组分，其主要包括包含片芯中聚合物组分的60％至100％的水不溶性聚合物，优选整个聚合物组分 在平板电脑核心。 药物组合物还可以包括包含水溶性和水不溶性聚合物的延长释放涂层。